Patents Represented by Attorney Maureen S. Gibbons
-
Patent number: 8278316Abstract: MCHR1 antagonists are provided having the following Formula I: wherein all of the variables are defined herein. Such compounds are useful for the treatment of MCHR1 mediated diseases, such as obesity, diabetes, IBD, depression, and anxiety.Type: GrantFiled: March 9, 2010Date of Patent: October 2, 2012Assignee: Bristol-Myers Squibb CompanyInventor: Saleem Ahmad
-
Patent number: 8217066Abstract: Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.Type: GrantFiled: October 1, 2010Date of Patent: July 10, 2012Assignee: Amira Pharmaceuticals, Inc.Inventors: Thomas Jon Seiders, Lucy Zhao, Jeannie M. Arruda, Brian Andrew Stearns, Yen Pham Truong, Jill Melissa Scott, John Howard Hutchinson, Nicholas Simon Stock, Deborah Volkots
-
Patent number: 7910747Abstract: Pyrazoloamides are provided which are phosphonate and phosphinate glucokinase activators that are useful in treating diabetes and related diseases and have the structure wherein is a pyrazoyl ring; R4 is —(CH2)n—Z—(CH2)m—PO(OR7)(OR8), —(CH2)nZ—(CH2)m—PO(OR7)R9, or —(CH2)nZ—(CH2)m—PO(R9)(R10); R5 and R6 are independently selected from H, alkyl and halogen; Y is R3(CH2)s, wherein R3 is aryl , s is 0, X is a bond; and n, Z, m, R4, R5, R6, and R7 are as defined herein; or a pharmaceutically acceptable salt thereof.Type: GrantFiled: June 28, 2007Date of Patent: March 22, 2011Assignee: Bristol-Myers Squibb CompanyInventors: Denis E. Ryono, Peter T. W. Cheng, Scott A. Bolton, Sean Chen, Yan Shi, Wei Meng, Joseph A. Tino
-
Patent number: 7888504Abstract: Compounds are provided which are glucokinase activators and thus are useful in treating diabetes and related diseases and have the structure wherein in the ring represents one or two double bonds; R1 is aryl or heteroaryl; R2 is halogen, cycloalkyl, heterocyclyl, aryl, or heteroaryl; R5 is as defined herein; Z is O, S, S(O), S(O)2, or NR5a; X is S, O, N, NR3, or CR3; Y is NCR4 or N4; R3, R4, and R5 are as defined herein; R8 is aryl or heteroaryl; R6 and R7 are independently H, halogen, or alkyl; m is 0 or 1; and n is 0 to 3, or a pharmaceutically acceptable salt thereof. A method for treating diabetes and related diseases employing the above compounds is also provided.Type: GrantFiled: June 28, 2007Date of Patent: February 15, 2011Assignee: Bristol-Myers Squibb CompanyInventors: Sean Chen, Peter T. W. Cheng, Rebecca A. Smirk
-
Patent number: 7851622Abstract: The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I. Additionally, the present application provides pharmaceutical compositions containing at least one compound according to Formula I and optionally at least one additional therapeutic agent. Finally, the present application provides methods for treating a patient suffering from an MCHR-1 modulated disease or disorder such as, for example, obesity, diabetes, depression or anxiety by administration of a therapeutically effective dose of a compound according to Formula I where R1, R1a, R1b, A, R3, R4, R5, R5b and R6 are as defined herein.Type: GrantFiled: April 25, 2008Date of Patent: December 14, 2010Assignee: Bristol-Myers Squibb CompanyInventors: William N. Washburn, Saleem Ahmad, Andres S. Hernandez
-
Patent number: 7772267Abstract: There are provided compounds according to formula I wherein the substitutents are as described herein. Further provided are methods of using such compounds for the treatment of nuclear hormone receptor-associated conditions, such as age related diseases, for example sarcopenia. Also provided are pharmaceutical compositions containing such compounds and processes for preparing some of the compounds of the invention. Other embodiments are also disclosed.Type: GrantFiled: October 31, 2007Date of Patent: August 10, 2010Assignee: Bristol-Myers Squibb CompanyInventors: Chong-qing Sun, Lawrence Hamann, David Augeri, Yingzhi Bi, Jeffrey Robl, Yan-Ting Huang, Tammy Wang, Alexandra Holubec, Ligaya Simpkins, James C. Sutton, James J. Li
-
Patent number: 7745447Abstract: The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I. Additionally, the present application provides pharmaceutical compositions containing at least one compound according to Formula I and optionally at least one additional therapeutic agent. Finally, the present application provides methods for treating a patient suffering from an MCHR-1 modulated disease or disorder such as, for example, obesity, diabetes, depression or anxiety by administration of a therapeutically effective dose of a compound according to Formula I.Type: GrantFiled: October 25, 2006Date of Patent: June 29, 2010Assignee: Bristol-Myers Squibb CompanyInventors: William N. Washburn, Saleem Ahmad, Khehyong Ngu
-
Patent number: 7732480Abstract: There are disclosed bicyclic compounds according to formula I, pharmaceutical compositions containing such compounds and methods of using such compounds in the treatment of androgen receptor-associated conditions, such as age-related diseases, for example sarcopenia, wherein R1, R2, R5, X and n are defined herein.Type: GrantFiled: October 31, 2007Date of Patent: June 8, 2010Assignee: Bristol-Myers Squibb CompanyInventors: James J. Li, Lawrence Hamann, Haixia Wang
-
Patent number: 7709647Abstract: The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the general Formula I: including all prodrugs, pharmaceutically acceptable salts and stereoisomers, R1, R2, R3, n, and Z are described herein.Type: GrantFiled: April 17, 2008Date of Patent: May 4, 2010Assignee: Bristol-Myers Squibb CompanyInventors: Chongqing Sun, William R. Ewing, Yanting Huang, Annapurna Pendri, Samuel Gerritz, Bruce A. Ellsworth, Natesan Murugesan
-
Patent number: 7696241Abstract: The present invention relates to bicyclic compounds according to formula I, pharmaceutical compositions containing such compounds and methods of using such compounds in the treatment of androgen receptor-associated conditions, such as age-related diseases, for example sarcopenia, wherein R1, R2, R5, X and n are defined herein.Type: GrantFiled: March 2, 2005Date of Patent: April 13, 2010Assignee: Bristol-Myers Squibb CompanyInventors: James J. Li, Lawrence Hamann, Haixia Wang
-
Patent number: 7635699Abstract: Compounds are provided having the formula (I) wherein X for each occurrence is N or C-A, and R, Y, A and n are as defined herein, which compounds are dipeptidyl peptidase IV inhibitors and as such are useful in treating diabetes and micro- and macrovascular complications of diabetes, such as retinopathy, neuropathy, and nephropathy. A method for treating diabetes and related diseases employing the above compounds is also provided.Type: GrantFiled: December 21, 2005Date of Patent: December 22, 2009Assignee: Bristol-Myers Squibb CompanyInventors: Wei Meng, Lawrence G. Hamann, Robert Brigance
-
Patent number: 7632837Abstract: The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the following general formula: including all prodrugs, solvates, pharmaceutically acceptable salts and stereoisomers, wherein A, B, R1, R2, R3 and R8 are described herein.Type: GrantFiled: June 16, 2006Date of Patent: December 15, 2009Assignee: Bristol-Myers Squibb CompanyInventors: Chongqing Sun, Yanting Huang, Doree F. Sitkoff, Taekyu Lee, William Ewing
-
Patent number: 7629342Abstract: The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the general Formula I and Formula II: including all prodrugs, pharmaceutically acceptable salts and stereoisomers, R1, R2, R3 and R4 are described herein.Type: GrantFiled: June 16, 2006Date of Patent: December 8, 2009Assignee: Bristol-Myers Squibb CompanyInventors: William R. Ewing, Yeheng Zhu, Bruce A. Ellsworth
-
Patent number: 7625923Abstract: The present invention relates to bicyclic compounds according to formula I, pharmaceutical compositions containing such compounds and methods of using such compounds in the treatment of androgen receptor-associated conditions, such as age-related diseases, for example sarcopenia, wherein R1, R2, R5, X, Y and n are defined herein.Type: GrantFiled: March 2, 2005Date of Patent: December 1, 2009Assignee: Bristol-Myers Squibb CompanyInventors: Alexandra Nirschl, James C. Sutton, Lawrence Hamann, Tammy Wang, Yan Zou, Chongqing Sun
-
Patent number: 7592454Abstract: The present application provides novel compounds according to Formula (I): including all stereoisomers, solvates, prodrug esters and pharmaceutically acceptable salt forms thereof, wherein R1, R4a, R5, R6, R7, R8, R9, m, and X are described herein. Additionally, the present application provides novel pharmaceutical compositions comprising at least one compound according to Formula (I). Further, the present application provides methods of treating a patient in need comprising administering a therapeutically effective amount of at least one compound according to Formula (I).Type: GrantFiled: April 13, 2005Date of Patent: September 22, 2009Assignee: Bristol-Myers Squibb CompanyInventors: Taekyu Lee, Wei Deng, Albert J. Robichaud
-
Patent number: 7589193Abstract: A compound of the formula I A method is also provided for treating diabetes and related diseases employing the above compound alone or in combination with another therapeutic agent.Type: GrantFiled: September 23, 2005Date of Patent: September 15, 2009Assignee: Bristol-Myers Squibb CompanyInventors: William Washburn, Wei Meng
-
Patent number: 7589088Abstract: Compounds are provided having the formula (I) wherein R, B, X and Y are as defined herein.Type: GrantFiled: December 21, 2005Date of Patent: September 15, 2009Assignee: Bristol-Myers Squibb CompanyInventors: Wei Meng, Lawrence G. Hamann, Robert Brigance
-
Patent number: 7572808Abstract: The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents, and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the following general formula: including all prodrugs, solvates, pharmaceutically acceptable salts and stereoisomers, wherein R1, R2, R3, R4 and R5 are described herein.Type: GrantFiled: June 16, 2006Date of Patent: August 11, 2009Assignee: Bristol-Myers Squibb CompanyInventors: Chongqing Sun, Philip M. Sher, Gang Wu, William R. Ewing, Yanting Huang, Taekyu Lee, Natesan Murugesan, Richard B. Sulsky
-
Patent number: 7557143Abstract: Thyroid receptor ligands are provided which have the general formula I wherein: R1 is R2 and R3 are the same or different and are hydrogen, halogen, alkyl of 1 to 4 carbons or cycloalkyl of 3 to 5 carbons, provided that at least one of R2 and R3 is other than hydrogen; R4 is R5 and R6 are the same or different and are selected from hydrogen, aryl, heteroaryl, alkyl, cycloalkyl, aralkyl or heteroaralkyl.Type: GrantFiled: April 15, 2004Date of Patent: July 7, 2009Assignee: Bristol-Myers Squibb CompanyInventors: Denis E. Ryono, Jon J. Hangeland, Todd J. Friends, Tamara Dejneka, Pratik Devasthale, Yolanda V. Caringal, Minsheng Zhang, Arthur M. P. Doweyko, Johan Malm, Andrei Sanin
-
Patent number: 7553836Abstract: The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I wherein R1a, R1b, R1c, Q, A, R3, W, D and R2 are defined herein. Additionally, the present application provides pharmaceutical compositions containing at least one compound according to Formula I and optionally at least one additional therapeutic agent. Finally, the present application provides methods for treating a patient suffering from an MCHR-1 modulated disease or disorder such as, for example, obesity, diabetes, depression or anxiety by administration of a therapeutically effective dose of a compound according to Formula I.Type: GrantFiled: February 5, 2007Date of Patent: June 30, 2009Assignee: Bristol-Myers Squibb CompanyInventor: Guohua Zhao